A Population‐Based Study of Cholinesterase Inhibitor Use for Dementia
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To examine current utilization patterns of cholinesterase inhibitor (ChEI) therapy for dementia to determine treatment duration, use in long‐term care, how often patients receive these drugs until death, and frequency of switching between the available ChEIs. DESIGN: A population‐based healthcare administrative database study. SETTING: Patients aged 66 and older from the Canadian province of Ontario who received a new prescription for a ChEI between June 1, 2000, and December 31, 2002. Patients were followed until discontinuation of ChEI therapy, death, or end of the observation period (March 31, 2005). PARTICIPANTS: Twenty‐eight thousand nine hundred and sixty‐one patients, including 4,601 residing in long‐term care, mean age 80, 63% female. MEASUREMENTS: Information on diagnosis, medical comorbidity, physician visits, and concomitant medication use was obtained. Estimates of duration of continuous use were determined. The percentage of patients who remained on the initial dose prescribed, the proportion who switched to a second ChEI, and the percentage who remained on ChEIs until death were calculated. RESULTS: Patients had on average more than 26 physician visits in the year before ChEI therapy, but only 28% had seen a dementia specialist. Concomitant use of potentially inappropriate medications (strongly anticholinergic medications and benzodiazepines) was noted in 37% of patients. The average length of treatment for all patients was 866 days. Many patients (43%) remained on the initial dose prescribed, 6% switched to another ChEI, and 19% died while on ChEI therapy. CONCLUSION: Elderly patients with dementia are treated for lengthy periods of time with ChEIs in the community and in long‐term care facilities. Further research is required to determine whether these utilization patterns are appropriate. It is also unclear whether these results are generalizable to other populations without universal health coverage or drug formulary benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ancelin, M. L., Artero, S., Portet, F., Dupuy, A.-M., Touchon, J., & Ritchie, K. (2006) · BMJ · doi:10.1136/bmj.38740.439664.de · Cited by 589
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., & van den Bussche, H. (2005) · BMJ · doi:10.1136/bmj.331.7512.321 · Cited by 522
Doody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362
Drug-Induced Cognition Disorders in the Elderly: Incidence, Prevention and Management
Gray, S. L., Lai, K. V., & Larson, E. B. (1999) · Drug Safety · doi:10.2165/00002018-199921020-00004 · Cited by 190 · cited 1×
“Benzodiazepines cause sedation, memory difficulties, psychomotor slowing, and impaired vigilance.(16) Although evidence of benzodiazepines causing or exacerbating cognitive impairment in dementia from epidemiological studies is mixed,(23) studies of potentially reversible dementia have implicated benzodiazepines as co…”
BackgroundRaskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P., & Damaraju, C. V. (2004) · Archives of Neurology · doi:10.1001/archneur.61.2.252 · Cited by 167
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease
Thompson, S., Lanctôt, K. L., & Herrmann, N. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.425 · Cited by 109
Self-citation
Cited by
Jaakkimainen, R. L., Bronskill, S. E., Tierney, M. C., Herrmann, N., Green, D., Young, J., Ivers, N., Butt, D., Widdifield, J., & Tu, K. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160105 · Cited by 305
Self-citationHogan, D. B., Bailey, P., Black, S., Carswell, A., Chertkow, H., Clarke, B., Cohen, C., Fisk, J. D., Forbes, D., Man-Son-Hing, M., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.081103 · Cited by 167
“In Canada, the usual prescribers of cholinesterase inhibitors are family physicians.(46) This is in sharp contrast to the United Kingdom, where it is recommended that only specialists in the care of patients with dementia (specialists in psychiatry, neurology, geriatric medicine or geriatric psychiatry) initiate treat…”
BackgroundSystematic review: representativeness of participants in RCTs of acetylcholinesterase inhibitors
Leinonen, A., Koponen, M., & Hartikainen, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124500 · Cited by 64
Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial
Campbell, N. L., Perkins, A. J., Gao, S., Skaar, T. C., Li, L., Hendrie, H. C., Fowler, N., Callahan, C. M., & Boustani, M. A. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14827 · Cited by 58
Metadata
- Authors
- Herrmann, N., Gill, S. S., Bell, C. M., Anderson, G. M., Bronskill, S. E., Shulman, K. I., Fischer, H. D., Sykora, K., Shi, H. S., & Rochon, P. A.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2007-08-14
- Volume
- 55
- Issue
- 10
- Pages
- 1517-1523
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W1563993722
- Cited by
- 78
- References
- 6
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Population‐Based Study of Cholinesterase Inhibitor Use for Dementia. https://app.cochat.ai/papers/10.1111/j.1532-5415.2007.01377.x
- The paper
- Herrmann, N., Gill, S. S., Bell, C. M., Anderson, G. M., Bronskill, S. E., Shulman, K. I., Fischer, H. D., Sykora, K., Shi, H. S., & Rochon, P. A. (2007). A Population‐Based Study of Cholinesterase Inhibitor Use for Dementia. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2007.01377.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.